Recombinant humanized anti-IL-6R antibody (Hisun Pharma)

重组人源化IL-6R单抗（海正药业）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant humanized anti-IL-6R antibody (Hisun Pharma)
Drug Alias Name重组抗白介素-6受体人源化单抗HS-628
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsArthritis, RheumatoidArthritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesZhejiang Hisun Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Hisun Pharmaceutical Co LtdHisun Pharmaceutical (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsArthritis

Other Information

ATC CodeN/A
Related LinksN/A